Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials - Summary - MDSpire
Advertisement
Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials
To assess baseline disease severity among patients in clinical studies of topical therapies for atopic dermatitis (AD) and compare it with pivotal clinical trials of systemic therapies.
Approach:
Study Design: A review of randomized controlled trials (RCTs) of topical therapies for AD published between January 1, 2010, and May 1, 2025, was conducted, focusing on baseline disease severity assessments.
Data Extraction: Data were extracted from 59 RCTs, including baseline mean data for various disease severity assessments such as EASI, affected BSA, SCORAD, IGA, itch NRS/VAS, POEM, and DLQI.
Key Findings:
Many patients with AD in topical therapy RCTs had high disease burden.
Patient-reported disease burden in topical therapy RCTs overlapped substantially with that reported in systemic therapy pivotal RCTs.
Topical therapies may be effective in patients with more extensive AD.
Interpretation:
Limitations:
Few studies exclusively assessed pediatric AD.
Baseline IGA and SCORAD were not widely reported, limiting comprehensive comparison.
by Melinda J. Gooderham, H. Chih-ho Hong, Charles Lynde, Yvette Miller-Monthrope, Vimal H. Prajapati, Julien Ringuet, Irina Turchin, Jensen Yeung, Kim A. Papp
A randomized clinical trial found that a team-based connected health model achieved equivalent improvements in atopic dermatitis severity and symptoms compared with conventional in-person care over 12 months.
Poorer dermatology-related quality of life was associated with greater mental health issues, while habitual probiotic intake showed no measurable relationship with these outcomes.
